Market Overview

BioPharmX Says Phase 2b Trial Met Endpoints


Biopharmx Corp (NYSE: BPMX) shares spiked higher Tuesday morning after the company announced its Phase 2b trial of BPX-04 for Populopustular Rosacea has met both primary and secondary endpoints and was well tolerated.

This news pushed BioPharmX from 88 cents to $1.27 per share, but the stock traded around 84 cents at time of publication.

Related Links:

Akorn Receives FDA Warning Letter, Says It's Committed To Resolving Issues

Acer Therapeutics Shares Plunge On FDA Complete Response Letter


Related Articles (BPMX)

View Comments and Join the Discussion!

Posted-In: Biotech News Penny Stocks Markets General